NKGNNKGen Biotech, Inc.

Nasdaq nkgenbiotech.com


$ 1.49 $ 0.08 (5.63 %)    

Tuesday, 28-May-2024 15:59:14 EDT
QQQ $ 454.82 $ 1.73 (0.38 %)
DIA $ 398.57 $ -2.04 (-0.52 %)
SPY $ 530.36 $ 0.37 (0.07 %)
TLT $ 91.26 $ -1.31 (-1.43 %)
GLD $ 225.37 $ 2.27 (1.05 %)
$ 1.5
$ 1.57
$ 0.00 x 0
$ 0.00 x 0
$ 1.46 - $ 1.60
$ 0.78 - $ 12.88
184,817
na
32.9M
$ -0.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-20-2024 03-31-2024 10-Q
2 04-16-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 07-02-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-nkgen-biotech-stock-is-moving-higher-monday

NKGen Biotech shares are trading higher Monday after the company's SNK01 NK Cell Therapy was cleared to begin a Phase 2 tri...

Core News & Articles
Market-Moving News for May 20th
05/20/2024 12:37:59

PTCT: 27% | PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation NKGN: 81% | NK...

Core News & Articles
Market-Moving News for April 29th
04/29/2024 12:46:23

TSLA: 14% | Tesla shares are trading higher on reports the company will partner with Baidu for mapping and navigation for Full ...

 nkgen-biotech-announces-fda-clearance-of-ind-application-for-snk01-nk-cell-therapy-in-parkinsons-disease

NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients...

 whats-going-on-with-nano-cap-nkgen-biotech-stock-on-monday

Latest on NKGen Biotech Inc (NASDAQ: NKGN) as shares surge 25.2% on high volume. Insights into NK cell therapy for neurodegener...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION